UA123159C2 - Способи лікування розсіяного склерозу з використанням сполук піримідину і піридину з btk-інгібувальною активністю - Google Patents

Способи лікування розсіяного склерозу з використанням сполук піримідину і піридину з btk-інгібувальною активністю Download PDF

Info

Publication number
UA123159C2
UA123159C2 UAA201806687A UAA201806687A UA123159C2 UA 123159 C2 UA123159 C2 UA 123159C2 UA A201806687 A UAA201806687 A UA A201806687A UA A201806687 A UAA201806687 A UA A201806687A UA 123159 C2 UA123159 C2 UA 123159C2
Authority
UA
Ukraine
Prior art keywords
amino
pyrimidin
phenoxyphenyl
shi
phenyl
Prior art date
Application number
UAA201806687A
Other languages
English (en)
Ukrainian (uk)
Inventor
Таммі Делловейд
Тамми ДЕЛЛОВЕЙД
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of UA123159C2 publication Critical patent/UA123159C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
UAA201806687A 2015-11-17 2016-11-16 Способи лікування розсіяного склерозу з використанням сполук піримідину і піридину з btk-інгібувальною активністю UA123159C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562256199P 2015-11-17 2015-11-17
PCT/US2016/062154 WO2017087445A1 (en) 2015-11-17 2016-11-16 Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity

Publications (1)

Publication Number Publication Date
UA123159C2 true UA123159C2 (uk) 2021-02-24

Family

ID=57460611

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201806687A UA123159C2 (uk) 2015-11-17 2016-11-16 Способи лікування розсіяного склерозу з використанням сполук піримідину і піридину з btk-інгібувальною активністю

Country Status (27)

Country Link
US (2) US10716788B2 (OSRAM)
EP (2) EP3377484B1 (OSRAM)
JP (1) JP6891173B2 (OSRAM)
KR (1) KR102780243B1 (OSRAM)
CN (1) CN108884076B (OSRAM)
AU (1) AU2016357735B2 (OSRAM)
BR (1) BR112018007517B1 (OSRAM)
CA (1) CA3002224A1 (OSRAM)
CL (1) CL2018001252A1 (OSRAM)
DK (1) DK3377484T3 (OSRAM)
ES (1) ES2964946T3 (OSRAM)
FI (1) FI3377484T3 (OSRAM)
HR (1) HRP20231547T1 (OSRAM)
HU (1) HUE064244T2 (OSRAM)
IL (1) IL258978B (OSRAM)
LT (1) LT3377484T (OSRAM)
MX (1) MX386146B (OSRAM)
MY (1) MY199473A (OSRAM)
NZ (1) NZ741294A (OSRAM)
PH (1) PH12018500736A1 (OSRAM)
PL (1) PL3377484T3 (OSRAM)
PT (1) PT3377484T (OSRAM)
RS (1) RS64908B1 (OSRAM)
SI (1) SI3377484T1 (OSRAM)
UA (1) UA123159C2 (OSRAM)
WO (1) WO2017087445A1 (OSRAM)
ZA (1) ZA201802348B (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI858413B (zh) * 2015-11-04 2024-10-11 德商默克專利有限公司 具有ｂｔｋ抑制活性之嘧啶及吡啶化合物之用途
US10716788B2 (en) * 2015-11-17 2020-07-21 Merck Patent Gmbh Methods for treating MS using pyrimidine and pyridine compounds with BTK inhibitory activity
WO2019243223A1 (en) * 2018-06-19 2019-12-26 Merck Patent Gmbh Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain
JP7724151B2 (ja) * 2018-07-20 2025-08-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 多発性硬化症の治療及び予防方法における使用のための置換されたアミノ－ピリミジン化合物
MX2022008875A (es) 2020-01-20 2022-08-11 Genzyme Corp Inhibidores terapeuticos de tirosina quinasa para esclerosis multiple recidivante (emr).
CN112250666B (zh) * 2020-10-09 2022-01-14 广东东阳光药业有限公司 取代的嘧啶类化合物及其用途
CA3200332A1 (en) * 2020-12-02 2022-06-09 Telios Pharma, Inc. Methods and compositions for treating an ophthalmic condition
CA3201936A1 (en) 2020-12-10 2022-06-16 Minhua Chen Crystal form of tolebrutinib and preparation method thereof
US11866421B2 (en) 2021-05-31 2024-01-09 Epigen Biosciences, Inc. Pyrimidine and pyridine amine compounds and usage thereof in disease treatment
AU2023286839A1 (en) 2022-06-24 2025-02-13 Merck Patent Gmbh Treatment regimen for autoimmune diseases and inflammatory diseases
CN117986236B (zh) * 2022-11-07 2024-12-31 天津征程医药科技有限公司 氘代的嘧啶衍生物以及包含该化合物的药物组合物
WO2025096900A1 (en) * 2023-11-03 2025-05-08 Board Of Regents, The University Of Texas System Synthetic network materials and methods of making and use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002514195A (ja) * 1996-12-05 2002-05-14 アムジエン・インコーポレーテツド 置換ピリミジン化合物およびそれの使用
WO2005095400A1 (en) 2004-03-30 2005-10-13 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of jak and other protein kinases
GB0512844D0 (en) * 2005-06-23 2005-08-03 Novartis Ag Organic compounds
EP2526934B1 (en) * 2006-09-22 2015-12-09 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
WO2009055418A1 (en) * 2007-10-22 2009-04-30 Smithkline Beecham Corporation Pyridosulfonamide derivatives as pi3 kinase inhibitors
CA2773182A1 (en) 2009-09-10 2011-03-17 F. Hoffmann-La Roche Ag Inhibitors of jak
KR101301533B1 (ko) 2010-02-09 2013-09-04 한미사이언스 주식회사 암세포 성장 억제 효과를 갖는 신규 피리미딘 유도체
KR20180084153A (ko) * 2011-06-10 2018-07-24 메르크 파텐트 게엠베하 Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법
TW201414734A (zh) * 2012-07-10 2014-04-16 Takeda Pharmaceutical 氮雜吲哚衍生物
WO2014068527A1 (en) * 2012-11-02 2014-05-08 Pfizer Inc. Bruton's tyrosine kinase inhibitors
WO2014093230A2 (en) * 2012-12-10 2014-06-19 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
WO2014163161A1 (ja) * 2013-04-04 2014-10-09 武田薬品工業株式会社 複素環化合物
NZ754039A (en) * 2013-06-26 2021-06-25 Abbvie Inc Primary carboxamides as btk inhibitors
RU2712220C2 (ru) * 2013-07-31 2020-01-27 Мерк Патент Гмбх Пиридины, пиримидины и пиразины в качестве ингибиторов тирозинкиназы брутона и их применение
CA2918938C (en) 2013-09-22 2021-05-18 Calitor Sciences, Llc Substituted aminopyrimidine compounds and methods of use
TWI858413B (zh) * 2015-11-04 2024-10-11 德商默克專利有限公司 具有ｂｔｋ抑制活性之嘧啶及吡啶化合物之用途
US10716788B2 (en) * 2015-11-17 2020-07-21 Merck Patent Gmbh Methods for treating MS using pyrimidine and pyridine compounds with BTK inhibitory activity

Also Published As

Publication number Publication date
ES2964946T3 (es) 2024-04-10
BR112018007517B1 (pt) 2023-09-26
MX2018005463A (es) 2018-08-01
IL258978A (en) 2018-07-31
KR102780243B1 (ko) 2025-03-14
EP4295910A2 (en) 2023-12-27
EP3377484A1 (en) 2018-09-26
CA3002224A1 (en) 2017-05-26
CN108884076B (zh) 2021-07-30
US10716788B2 (en) 2020-07-21
FI3377484T3 (fi) 2023-11-30
EP3377484B1 (en) 2023-09-06
WO2017087445A1 (en) 2017-05-26
RU2018120151A3 (OSRAM) 2020-03-24
HUE064244T2 (hu) 2024-02-28
BR112018007517A2 (pt) 2018-10-23
HRP20231547T1 (hr) 2024-03-15
SI3377484T1 (sl) 2024-02-29
NZ741294A (en) 2023-07-28
ZA201802348B (en) 2020-08-26
MY199473A (en) 2023-10-31
CN108884076A (zh) 2018-11-23
PH12018500736A1 (en) 2018-10-01
JP2018538264A (ja) 2018-12-27
AU2016357735A1 (en) 2018-04-26
JP6891173B2 (ja) 2021-06-18
RS64908B1 (sr) 2023-12-29
CL2018001252A1 (es) 2018-08-17
LT3377484T (lt) 2023-12-27
KR20180080243A (ko) 2018-07-11
PT3377484T (pt) 2023-12-14
AU2016357735B2 (en) 2021-01-14
IL258978B (en) 2021-04-29
RU2018120151A (ru) 2019-12-18
US20200316068A1 (en) 2020-10-08
PL3377484T3 (pl) 2024-04-08
US20170136018A1 (en) 2017-05-18
DK3377484T3 (da) 2023-11-27
MX386146B (es) 2025-03-18
EP4295910A3 (en) 2024-03-20

Similar Documents

Publication Publication Date Title
UA123159C2 (uk) Способи лікування розсіяного склерозу з використанням сполук піримідину і піридину з btk-інгібувальною активністю
ES2923760T3 (es) Composiciones y métodos para la producción de compuestos de pirimidina y piridina con actividad inhibidora de BTK
CN104066718B (zh) 取代苯化合物
JP7295169B2 (ja) Ｂｔｋ阻害活性を有するピリミジン及びピリジン化合物を用いた癌の治療方法
US9233111B2 (en) Pyrrolo pyrimidine derivatives
JP5644499B2 (ja) ２，４−ジアミノピリミジン化合物
RS50755B (sr) Supstituisani aril i heteroaril derivati kao modulatori metabolizma i profilakse i lečenje poremećaja proisteklih iz toga
TWI230159B (en) Novel compounds useful as reversible inhibitors of cysteine proteases
CN105579452B (zh) 作为NIK抑制剂的新型3‑(1H‑吡唑‑4‑基)‑1H‑吡咯并[2,3‑c]吡啶衍生物
JP2019014732A (ja) アリール置換またはヘテロアリール置換ベンゼン化合物
KR20160095159A (ko) 치환된 디아미노피리미딜 화합물, 이의 조성물, 및 이를 사용한 치료방법
CN109912594A (zh) 作为fgfr抑制剂的双环杂环
US9981962B2 (en) Pyrazole derivatives as NIK inhibitors
CN102933579A (zh) 新的ccr2受体拮抗剂及其用途
MX2007008402A (es) Derivados de pirimidinil y piridinil sustituidos como moduladores del metabolismo y el tratamiento de desordenes relacionados con el mismo.
US10323045B2 (en) Thienopyrimidine derivatives as NIK inhibitors
RS65962B1 (sr) Inhibitori nek7 kinaze
KR20140040774A (ko) 이미다조피리딘 화합물
CN102382088A (zh) 作为趋化因子受体调节剂的3-氨基环戊烷甲酰胺类
TW201629012A (zh) 雜環衍生物及其用途（一）
JP7043483B2 (ja) 二環式プロリン化合物
EA031310B1 (ru) Производные пиперидина и азепина как модуляторы рецептора прокинетицина
CN119384408A (zh) 用于靶向蛋白降解的双功能分子
TW201940169A (zh) 化合物
HK1178147B (en) New ccr2 receptor antagonists and uses thereof